Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/neu–Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials

(2012) Edith A. Perez et al.   MAYO CLINIC PROCEEDINGS

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

(2010) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer

(2009) Prithviraj Bose et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer

(2009) M. Ray et al.   ONCOLOGIST

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

(2008) John P. Crown et al.   BREAST CANCER RESEARCH AND TREATMENT

Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients

(2008) Noor Al-Dasooqi et al.   INVESTIGATIONAL NEW DRUGS

Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer

(2008) Anna Maria Storniolo et al.   JOURNAL OF CLINICAL ONCOLOGY

The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer

(2008) Chau Dang et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial

(2008) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?

(2008) T. E. Stinchcombe et al.   ONCOLOGIST